

CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND

INSTRUCTIONS FOR ENTRY

IN THE SPECIFICATION:

Q1 As a result of these procedures, the disease specific markers plasma protease (C1) inhibitor having a molecular weight of about 1826 daltons and a sequence of SEQ ID NO: 1, molecular weight of about 1560 daltons and a sequence of SEQ ID NO: 2, molecular weight of about 1186 and a sequence of SEQ ID NO: 3 (see Fig. 1, Band 2) related to Alzheimers disease were found.

IN THE CLAIMS:

Q2 Claim 1. A biopolymer marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. or at least one analyte thereof useful in indicating at least one particular disease state.

Claim 18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:

Q3 at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof related to said disease state; and means for determining binding between said biochemical material and said biomolecule; whereby at least one analysis to determine a presence of a marker, analyte thereof, or a

Q3 biochemical material specific thereto, is carried out on a sample.

Claim 29. Polyclonal antibodies produced against a marker sequence ID selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof in at least one animal host.

Q4 Claim 30. An antibody that specifically binds a biopolymer including a marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof.

Claim 33. A process for identifying therapeutic avenues related to a disease state comprising:

Q5 conducting an analysis as provided by the kit of claim 18; and
interacting with a biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. or at least one analyte thereof;
whereby therapeutic avenues are developed.

Claim 34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof.
